Individual Cognitive Stimulation Therapy for dementia

Conditions

Dementia Mental and Behavioural Disorders Unspecified dementia

Martin Orrell, Lauren Yates, Phuong Leung, Sujin Kang, Zoë Hoare et al. (18 authors)

PLoS Medicine2017-03-28159 citations

10.1371/journal.pmed.1002269

Field-testing phase of the development of individual cognitive stimulation therapy (iCST) for dementia

Lauren Yates, Vasiliki Orgeta, Phuong Leung, Aimee Spector, Martin Orrell

BMC Health Services Research2016-07-0817 citations

10.1186/s12913-016-1499-y

Individual cognitive stimulation therapy for dementia: a clinical effectiveness and cost-effectiveness pragmatic, multicentre, randomised controlled trial.

Orgeta V, Leung P, Yates L, Kang S, Hoare Z, Henderson C, Whitaker C, Burns A, Knapp M, Leroi I, Moniz-Cook ED, Pearson S, Simpson S, Spector A, Roberts S, Russell IT, de Waal H, Woods RT, Orrell M.

2015-08-0169 citations

10.3310/hta19640

Service users' involvement in the development of individual Cognitive Stimulation Therapy (iCST) for dementia: a qualitative study.

Yates LA, Orrell M, Spector A, Orgeta V.

2015-02-0617 citations

10.1186/s12877-015-0004-5

Interventions

Individualised CST vs no treatment (control) iCST sessions will last for 30 minutes and take place 3 times a week for 25 weeks.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Meet Diagnostic and Statistical Manual of Mental Disorders 4th edition (DSM IV) criteria for dementia 2. Score 10 or above on the Mini Mental State Examination (MMSE) 3. Some ability to communicate and understand 4. See/hear well enough to participate 5. No major physical illness or disability affecting their participation 6. Male or female, no age restrictions Additional criteria will include living in the community and regular availability of a carer (or friend or befriender) to participate in the sessions.

Exclusion criteria

Exclusion criteria: People with dementia not meeting the criteria for individual work (living in a care home, no available family carer) but who are eligible for group CST will be linked up with the trial of maintenance group CST (NIHR programme).

Design outcomes

Primary

Measure	Time frame
1. Alzheimer's Disease Assessment Scale - Cognitive subscale (ADAS-Cog) (Rosen et al., 1984) 2. Quality of Life-Alzheimer's disease Scale (QoL-AD) (Logsdon et al., 1999) 3. Short Form-12 (SF-12) (Ware, Kosinski, and Keller, 1996) Assessments will take place at baseline (pre iCST), 13 weeks (to safeguard loss to follow-up) and 26 weeks.	—

Secondary

Measure	Time frame
1. Client Service Receipt Inventory (Beecham & Knapp, 1992) 2. Dementia-related Quality of Life (DEMQOL) (Smith et al., 2005) 3. Behaviour 4. Neuropsychiatric Inventory (NPI) (Cummings et al. 1994) 5. Bristol Activities of Daily Living Scale (BADLS) (Bucks et al, 1996) 6. Hospital Anxiety and Depression Scale (HADS) (Zigmond and Snaith, 1983) 7. EQ-5D (EuroQol group, 1990) Assessments will take place at baseline, 13 and 26 weeks.	—

Measure

Time frame

1. Client Service Receipt Inventory (Beecham & Knapp, 1992) 2. Dementia-related Quality of Life (DEMQOL) (Smith et al., 2005) 3. Behaviour 4. Neuropsychiatric Inventory (NPI) (Cummings et al. 1994) 5. Bristol Activities of Daily Living Scale (BADLS) (Bucks et al, 1996) 6. Hospital Anxiety and Depression Scale (HADS) (Zigmond and Snaith, 1983) 7. EQ-5D (EuroQol group, 1990) Assessments will take place at baseline, 13 and 26 weeks.

—

Countries

United Kingdom

Outcome results

None listed